• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Biogen Inc.

    5/6/25 5:26:23 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIIB alert in real time by email
    FWP 1 d905655dfwp.htm FWP FWP

    Filed pursuant to Rule 433

    Registration No.: 333-286915

    Free Writing Prospectus dated May 6, 2025

    Relating to Preliminary Prospectus Supplement dated May 6, 2025

    (to Prospectus dated May 1, 2025)

    $1,750,000,000

    Biogen Inc.

    $400,000,000 5.050% Senior Notes Due 2031

    $650,000,000 5.750% Senior Notes Due 2035

    $700,000,000 6.450% Senior Notes Due 2055

    PRICING TERM SHEET

    $400,000,000 5.050% Senior Notes Due 2031

     

    Issuer    Biogen Inc.
    Principal Amount    $400,000,000
    Maturity Date    January 15, 2031
    Interest Payment Dates    Semi-annually, each January 15 and July 15, commencing January 15, 2026
    Benchmark Treasury    3.875% due April 30, 2030
    Benchmark Treasury Price; Yield    99-28 1⁄4 / 3.901%
    Spread to Benchmark Treasury    115 basis points
    Yield to Maturity    5.051%
    Interest Rate    5.050% per annum beginning on the Issue Date
    Issue Price (Price to Public)    99.981%
    Optional Redemption   

    Make-whole call, in whole or in part, as set forth in the preliminary prospectus supplement (Treasury Rate (as defined in the preliminary prospectus supplement) plus 20 basis points) at any time prior to December 15, 2030 (one month prior to the maturity date of the notes due 2031)

     

    Par call, in whole or in part, at any time on or after December 15, 2030 (one month prior to the maturity date of the notes due 2031)

    CUSIP/ISIN    09062XAN3/US09062XAN30


    $650,000,000 5.750% Senior Notes Due 2035

     

    Issuer    Biogen Inc.
    Principal Amount    $650,000,000
    Maturity Date    May 15, 2035
    Interest Payment Dates    Semi-annually, each May 15 and November 15, commencing November 15, 2025
    Benchmark Treasury    4.625% due February 15, 2035
    Benchmark Treasury Price; Yield    102-15+ / 4.310%
    Spread to Benchmark Treasury    145 basis points
    Yield to Maturity    5.760%
    Interest Rate    5.750% per annum beginning on the Issue Date
    Issue Price (Price to Public)    99.924%
    Optional Redemption   

    Make-whole call, in whole or in part, as set forth in the preliminary prospectus supplement (Treasury Rate (as defined in the preliminary prospectus supplement) plus 25 basis points) at any time prior to February 15, 2035 (three months prior to the maturity date of the notes due 2035)

     

    Par call, in whole or in part, at any time on or after February 15, 2035 (three months prior to the maturity date of the notes due 2035)

    CUSIP/ISIN    09062XAL7/US09062XAL73


    $700,000,000 6.450% Senior Notes Due 2055

     

    Issuer    Biogen Inc.
    Principal Amount    $700,000,000
    Maturity Date    May 15, 2055
    Interest Payment Dates    Semi-annually, each May 15 and November 15, commencing November 15, 2025
    Benchmark Treasury    4.500% due November 15, 2054
    Benchmark Treasury Price; Yield    94-28+ / 4.826%
    Spread to Benchmark Treasury    165 basis points
    Yield to Maturity    6.476%
    Interest Rate    6.450% per annum beginning on the Issue Date
    Issue Price (Price to Public)    99.657%
    Optional Redemption   

    Make-whole call, in whole or in part, as set forth in the preliminary prospectus supplement (Treasury Rate (as defined in the preliminary prospectus supplement) plus 25 basis points) at any time prior to November 15, 2054 (six months prior to the maturity date of the notes due 2055)

     

    Par call, in whole or in part, at any time on or after November 15, 2054 (six months prior to the maturity date of the notes due 2055)

    CUSIP/ISIN    09062XAM5/US09062XAM56


    Terms Applicable to All Tranches

     

    Expected Ratings*    Baa2 (stable) / BBB+ (stable) (Moody’s/S&P)
    Trade Date    May 6, 2025
    Settlement Date**    May 12, 2025
    Change of Control    Upon the occurrence of a Change of Control Triggering Event (as defined in the preliminary prospectus supplement to which this pricing term sheet relates) with respect to a series of notes, Biogen Inc. will be required to make an offer to purchase the notes of such series at a price equal to 101% of their principal amount plus accrued and unpaid interest to but not including the date of repurchase.
    Joint Book-Running Managers   

    BofA Securities, Inc.

    Citigroup Global Markets Inc.

    J.P. Morgan Securities LLC

    Deutsche Bank Securities Inc.

    Mizuho Securities USA LLC

    Morgan Stanley & Co. LLC

    U.S. Bancorp Investments, Inc.

    Wells Fargo Securities, LLC

    Co-Managers   

    BBVA Securities Inc.

    Scotia Capital (USA) Inc.

    TD Securities (USA) LLC

    Academy Securities, Inc.

    Blaylock Van, LLC

    Loop Capital Markets LLC

     

    *

    None of the securities ratings is a recommendation to buy, sell or hold the notes. Each rating may be subject to revision or withdrawal at any time, and should be evaluated independently of any other rating.

    **

    Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the date that is one business day preceding the settlement date will be required, by virtue of the fact that the notes initially will settle T+4, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of notes who wish to trade the notes prior to the date that is one business day preceding the settlement date should consult their own advisors.

    The issuer has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the Securities and Exchange Commission (“SEC”) for the offerings to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and these offerings. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offerings will arrange to send you the prospectus if you request it by calling BofA Securities, Inc. toll free at 1 (800) 294-1322; Citigroup Global Markets Inc. toll free at 1 (800) 831-9146; or J.P. Morgan Securities LLC collect at 1 (212) 834-4533.

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED (OTHER THAN ANY STATEMENT RELATING TO THE IDENTITY OF THE LEGAL ENTITY AUTHORIZING OR SENDING THIS COMMUNICATION IN A NON-US JURISDICTION). SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION HAVING BEEN SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

    Get the next $BIIB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIIB

    DatePrice TargetRatingAnalyst
    4/28/2025$118.00Buy → Hold
    HSBC Securities
    4/4/2025Buy → Hold
    Argus
    2/11/2025$160.00Mkt Perform
    Bernstein
    1/2/2025$315.00 → $138.00Overweight → Neutral
    Piper Sandler
    12/20/2024$230.00 → $164.00Outperform → Market Perform
    BMO Capital Markets
    12/16/2024$175.00Buy → Hold
    Stifel
    12/10/2024$178.00Neutral
    BofA Securities
    12/9/2024$250.00 → $180.00Buy → Hold
    Jefferies
    More analyst ratings

    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

      9/16/24 6:52:10 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

      9/16/24 6:24:32 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

      3/25/24 4:41:37 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pangalos Menelas N

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 5:05:17 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Minor Lloyd was granted 2,370 shares (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 4:54:06 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Patolawala Monish D was granted 2,370 shares, increasing direct ownership by 177% to 3,710 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 4:53:06 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    SEC Filings

    See more
    • Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOGEN INC. (0000875045) (Filer)

      7/7/25 4:10:34 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - BIOGEN INC. (0000875045) (Filer)

      6/23/25 4:18:57 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Biogen Inc.

      DEFA14A - BIOGEN INC. (0000875045) (Filer)

      6/2/25 9:20:36 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      5/5/25 4:17:10 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      2/20/24 9:13:26 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Biogen downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Biogen from Buy to Hold and set a new price target of $118.00

      4/28/25 8:32:10 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biogen downgraded by Argus

      Argus downgraded Biogen from Buy to Hold

      4/4/25 7:48:30 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bernstein initiated coverage on Biogen with a new price target

      Bernstein initiated coverage of Biogen with a rating of Mkt Perform and set a new price target of $160.00

      2/11/25 7:02:16 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

      Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S.1Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will eval

      6/30/25 7:30:12 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

      New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from

      6/27/25 10:00:23 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

      Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

      6/25/25 7:30:37 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BIIB
    Financials

    Live finance-specific insights

    See more
    • Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

      Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

      6/25/25 7:30:37 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

      Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and

      4/1/25 7:30:00 AM ET
      $BIIB
      $OGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment

    $BIIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biogen Inc.

      SC 13G/A - BIOGEN INC. (0000875045) (Subject)

      11/12/24 1:24:28 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biogen Inc.

      SC 13G/A - BIOGEN INC. (0000875045) (Subject)

      11/4/24 11:20:12 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Biogen Inc.

      SC 13G - BIOGEN INC. (0000875045) (Subject)

      10/16/24 12:11:53 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Leadership Updates

    Live Leadership Updates

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus

      1/8/25 8:00:00 AM ET
      $AGIO
      $BIIB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)